The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis

Zachary M. Saleh1 | Quintin P. Solano2 | Jeremy Louissaint3 | Peter Jepsen4,5 | Elliot B. Tapper3,6

1Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
2University of Michigan Medical School, Ann Arbor, MI, USA
3Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA
4Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
5Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
6Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

Correspondence
Zachary Saleh, MD3912 Taubman, SPC 5362
1500 E Medical Center Dr Ann Arbor, MI 48109-, USA.
Email: zsaleh@umich.edu

Funding information
National Institutes of Health, Grant/Award Numbers: NIDDK (1K23DK117055-01A1), T32DK062708

Abstract
Background: Cirrhosis is associated with increased perioperative risks related to hepatic decompensation. However, data are lacking regarding the incidence and outcomes of postoperative hepatic encephalopathy (HE).

Objective: To determine the incidence of HE postoperatively, factors associated with its development, and its association with in-hospital mortality.

Methods: Retrospective cohort study of 583 patients with cirrhosis undergoing non-hepatic surgery over a 10-year period. Outcomes included postoperative HE and in-hospital mortality and were, respectively, evaluated using multi-state modeling and Fine-Gray competing risk regression (with postoperative HE as a time-varying covariate).

Results: Overall, the median Model for End-Stage Liver Disease Sodium was 10, 61.7% had a history of ascites, 49.9% esophageal varices, and 34.6% HE. The most common surgeries including abdominal/non-bowel (33.3%), orthopedic (18.0%), and bowel (12.2%). A total of 42 (7.2%) patients developed HE postoperatively during admission. The cumulative risk of HE was 7.2%, which was most associated with a history of HE, ASA class, postoperative AKI, and postoperative infection. In-hospital mortality occurred in 34 (5.8%) individuals. Only ASA class was independently associated (HR 2.46, 95%CI 1.21–5.02), but there was a trend for postoperative HE (HR 1.71, 95%CI 0.73–3.98).

Discussion: HE is an uncommon but not rare postoperative complication that increases the risk of patient harm. This study implies its development is predictable. Consequently, at-risk patients should have consultation with a hepatologist before undergoing elective surgery.

Keywords
HE, hepatic decompensation, hepatic encephalopathy, manuscript info section: liver cirrhosis, MELD-na, mortality, outcome, perioperative risk, postoperative, surgery
INTRODUCTION

The perioperative risks of surgery are raised in persons with cirrhosis. Risk is determined in part by disease severity,\(^1\,^2\) the presence of portal hypertension, comorbidities,\(^3\,^4\,^5\,^6\) as well as the type and urgency of surgery.\(^7\,^8\) Understanding the specific risks incurred by patients undergoing surgery can inform perioperative planning and potentially reduce postoperative complications. For example, ascites increases the risk of postoperative wound healing, infection, and renal failure; however, with preoperative volume status optimization, persons with cirrhosis undergoing colectomy can experience reduced postoperative complications.\(^9\) Similarly, hepatic encephalopathy (HE) may benefit from optimization perioperatively with respect to lactulose dosing, adjunctive co-therapies, or avoidance of triggers such as benzodiazepines. It is suspected that HE is a common and modifiable cause of postoperative delirium in patients with cirrhosis,\(^10\) and postoperative delirium in general is associated with poor outcomes.\(^11\)

Additionally, HE can lead to numerous inpatient complications, such as falls\(^12\) and increased mortality.\(^13\,^14\) Data are lacking regarding whom will develop postoperative HE and whether this development is independently associated with poor outcomes.

Patients with cirrhosis undergoing surgery encounter clinicians with various experience anticipating and managing postoperative cirrhotic complications. It is thus important to understand the risk of and risk factors for postoperative HE in order to define the population who could benefit from interventions to mitigate those risks. We seek to evaluate the risk and impact of HE on patients requiring surgery by assessing the incidence of HE postoperatively and factors associated with its development. Herein, we examine the risk of postoperative HE as well as the association of postoperative HE on in-hospital mortality.

METHODS

Patient selection

We retrospectively evaluated patients \(\geq 18\) years of age with cirrhosis (using diagnosis codes) admitted to Michigan Medicine between 01/01/2009 and 01/01/2019 for surgery. The surgeries included intrabdominal, cardiac, head and neck, orthopedic, skin and soft-tissue, thoracic, and vascular procedures. Central nervous system procedures were not included given the difficulty in assessing etiology of alerted mental status in this patient population. Urological and obstetrics/gynecologic procedures were not included due to their sex-specific nature. Patients were excluded if they underwent any liver- or biliary-related surgery or underwent transjugular intrahepatic portosystemic shunt (TIPS) placement during the admission. The diagnosis of cirrhosis was confirmed using histological, imaging, and clinical criteria. A search of the electronic medical record with these criteria yielded 728 unique hospitalizations, 104 of which involved patients without cirrhosis. 26 patients who did not undergo a procedure from the above categories or also underwent hepatobiliary or TIPS-related procedures during the same admission, 8 of age \(<18\) years, and 7 patients who were never extubated following surgery. A total of 583 patients met the above criteria and were included in the analysis.

Study design

We collected demographic information and clinical information including cirrhosis etiology and prior complications (ongoing and/or resolved), home medications, history of TIPS placement, selected preoperative and postoperative medication administration (lactulose, rifaximin, non-selective beta blockers, diuretics, opioids, acetaminophen, NSAIDs, anti-psychotics, and benzodiazepines), disease severity scoring (Model for End-Stage Liver Disease Sodium [MELD-Na]),\(^16\) Child-Turcotte-Pugh [CTP] scoring system, Charlson Comorbidity Index, and American Society of Anesthesiologists [ASA] physical status classification), and Mayo Operative Risk Score.\(^3\) Surgical procedures were grouped into one of the following categories: abdominal; abdominal/nonbowel; cardiac; head & neck; incision and drainage; orthopedic; spine; thoracic; vascular. Data regarding the nature of the surgery (elective, urgent, emergent) and anesthesia type were also collected. Postoperative courses were reviewed for the development of HE (defined as gross disorientation that was clinically diagnosed as HE by an attending physician, documented in the electronic health record, and associated with a corresponding change in therapy or management) and time to onset. Postoperative courses were also analyzed for the development of postoperative

Key Summary

1. Summarize the established knowledge on this subject
   - Patients with cirrhosis have increased perioperative risks when undergoing surgery
   - HE is a known complication of cirrhosis and contributes to inpatient morbidity and mortality
   - Data are lacking regarding the factors associated with developing postoperative HE and the effect it has on outcomes
2. What are the significant and/or new findings of this study
   - 7.2% of patients with cirrhosis undergoing surgery developed postoperative HE
   - Risk factors associated with development of postoperative HE include history of HE, increasing ASA classification, postoperative AKI, and postoperative infection
   - Multivariable cox regression revealed a trend toward increased risk of in-hospital mortality with the development of postoperative HE
complications, such as infection, acute kidney injury (AKI), and hypoglycemia (serum glucose <70 mg/dL). Data were extracted utilizing EMERSE. Finally, data regarding patients’ hospital length of stay (LOS) and in-hospital mortality were extracted from the electronic health record.

**Statistical analysis**

The primary outcome was the risk of postoperative HE. To calculate the risk of postoperative HE, we used a multi-state model to account for the competing events of being discharged without HE and in-hospital death without preceding HE. In this 4-state model, patients could transition from the postoperative state (state 1) to three potential absorbing states: discharge without postoperative HE (state 2), the development of postoperative HE (state 3), and death without postoperative HE (state 4). Covariates included in the competing risk regression model were selected a priori and included age, MELD-Na, ASA class, history of HE, and history of ascites. We intended to analyze postoperative medications, such as benzodiazepines and opioids, however they did not show an association on univariable analysis.

We further sought to analyze factors associated with the risk of postoperative in-hospital mortality. Specifically, we assessed the risk of in-hospital mortality after the development of postoperative HE using Cox regression with postoperative HE as a time-dependent covariate. A history of overt HE was not included in the multivariable model to avoid multicollinearity with the development of postoperative HE. This study was approved by the University of Michigan Medical School Institutional Review Board on July 29, 2019, which includes conformation to 1975 Declaration of Helsinki where appropriate. Consent was not required for this deidentified retrospective chart review. Statistical analysis was performed using RStudio (version 1.2).

**RESULTS**

**Demographics and patient characteristics**

Baseline characteristics for the 583 patients are included in Table 1. Patients had a median age of 60 years and were predominantly White (85.4%), with a male predominance (61.9%). The two most common etiologies of cirrhosis were alcohol-related (34.8%) and chronic hepatitis C infection (18.5%), while 17.8% were cryptogenic/unknown etiologies. The median MELD score was 10 (IQR 8–17), median CTP score was 7 (IQR 6–8), and the median ASA classification of III (frequencies: ASA II (22), III (352), IV (197), V (9), unlisted (3)). A history of ascites, esophageal varices, and HE was present in 61.7%, 49.9% of patients, 34.6%, respectively. Overall, 65.4% of patients examined had decompensated cirrhosis. Approximately 21% had an outpatient prescription for lactulose and 10% for rifaximin.

**Surgical details**

The most common categories of surgical procedures performed were abdominal/non-bowel (33.3%) and orthopedic (18.0%) (Table 3, a detailed breakdown can be found in Supplemental Figure S1). Surgeries were elective in 52.1% of the operations examined. In the preoperative period, less than 6% of patients received lactulose, rifaximin, diuretics, or nonselective beta-blockers. Table 2 details some of the perioperative details. General anesthesia was administered in approximately 91% of the patients in each group. Analgesics were the most commonly administered postoperative medications, opioids (65.0%), acetaminophen (42.9%), and NSAIDs (10.1%). Benzodiazepines (11.7%), diuretics (13.4%), and nonselective beta blockers (2.9%) were administered infrequently postoperatively. Lactulose and rifaximin were administered postoperatively in 10.1% and 6.5% of patients, respectively. In terms of complications amongst all patients, 12.2% developed AKI, 3.6% developed hypoglycemia, and 20.8% developed an infection during their postoperative course.

**The risk of postoperative hepatic encephalopathy**

A total of 42 (7.2%) patients experienced in-hospital HE in the postoperative setting (Table 3). On postoperative day 15, the cumulative risk of postoperative HE was 6.0% overall. The risk increased to 12.9%, 7.2%, and 9.8% if there was a prior history of hepatic encephalopathy (Figure 1), ascites, or TIPS placement, respectively. Additionally, the risk of postoperative HE was increased with increasing ASA class (0% ASA II, 4.0% ASA III, 9.6% ASA IV, and 22.2% ASA V) and MELD-Na (7.9% MELD-Na ≥ 10 vs. 3.7% MELD-Na < 10). The unadjusted subdistribution hazard ratios for the development of postoperative HE was significantly associated with markers of disease severity including MELD-Na, ASA class, history of HE, history of ascites, and Mayo 30-day postoperative risk score (Table 4). Additionally, while CTP Class C patients comprised only 10.8% of the overall study population, they accounted for one third of all postoperative HE cases. Conversely, 43.4% of all patients were Class A, however, only 19% of Class A patients developed postoperative HE (Table 1).

Neither opioids (subdistribution HR 0.88, 95%CI 0.47–1.63) nor benzodiazepines (subdistribution HR 1.55, 95%CI 0.69–3.46) administered in the 48-h postoperative period significantly modified the risk of postoperative HE. Postoperative diuretics (subdistribution HR 1.32, 95%CI [0.59–2.99]), and nonselective beta blockers (subdistribution HR 1.75, 95%CI 0.41–7.43) were also not associated with increased risk of HE. Fine and Gray multivariable competing risk regression revealed a history of HE (subdistribution HR 4.12, 95%CI 2.07–8.21) and ASA class (subdistribution HR 2.12, 95%CI 1.25–3.60) as significant factors associated with postoperative HE (Table 4).

In terms of postoperative complications, 23% developed AKI, 2% developed hypoglycemia, and 45% developed an infection in the HE group, compared with 11%, 4%, and 19%, respectively, in the non-HE group. The most commonly diagnosed infections in the HE group
were sepsis (19%) and urinary tract infection (10%), and the most common in the non-HE group were urinary tract infection (5.9%) and sepsis (5.4%, Table 2). Both postoperative AKI (subdistribution HR 2.27, 95%CI 1.12–4.57) and infection (subdistribution HR 1.28, 95%CI 0.31–5.22) were associated with an increased risk of postoperative HE (Table 4).

**Table 1** Patient characteristics

|                          | All Patients N = 583 | Develop HE N = 42 | Did not Develop HE N = 541 | P-value |
|--------------------------|----------------------|-------------------|----------------------------|---------|
| Demographics             |                      |                   |                            |         |
| Age                      | 60 (13)              | 60 (14)           | 60 (13)                    | 0.71    |
| Sex, male                | 361 (61.9%)          | 24 (57.1%)        | 337 (62.3%)                |         |
| Race, non-white/non-Caucasian | 85 (14.6%)          | 4 (9.5%)          | 81 (15.0%)                 |         |
| BMI                      | 28.3 (9.0)           | 27.3 (7.8)        | 28.4 (9.0)                 | 0.69    |
| Baseline laboratory values|                      |                   |                            |         |
| Platelets                | 128 (102)            | 98 (97)           | 129 (101)                  | 0.21    |
| Na                       | 138 (5)              | 137 (6)           | 138 (5)                    | <0.05   |
| Creatinine               | 0.98 (0.62)          | 1.09 (0.49)       | 0.96 (0.62)                | 0.80    |
| Albumin                  | 3.6 (1.0)            | 3.0 (0.6)         | 3.6 (1.1)                  | <0.05   |
| Bilirubin, total         | 1.0 (1.2)            | 1.7 (2.5)         | 0.9 (1.0)                  | <0.05   |
| INR                      | 1.1 (0.3)            | 1.3 (0.3)         | 1.1 (0.3)                  | <0.05   |
| MELD-Na                  | 10.0 (9.0)           | 15.5 (10.7)       | 10.0 (9.0)                 | <0.05   |
| CTP score                | 7 (2.0)              | 8 (3.0)           | 7 (2.0)                    | <0.05   |
| —CTP Class A             | 253 (43.4%)          | 8 (19.0%)         | 245 (45.3%)                |         |
| —CTP class B             | 258 (44.3%)          | 20 (47.6%)        | 238 (44.0%)                |         |
| —CTP class C             | 63 (10.8%)           | 14 (33.3%)        | 49 (9.1%)                  |         |
| Cirrhosis details        |                      |                   |                            |         |
| Etiology, alcohol-related| 203 (34.8%)          | 16 (38.1%)        | 187 (34.6%)                |         |
| History of complications |                      |                   |                            |         |
| —Ascites                 | 360 (61.7%)          | 32 (76.2%)        | 328 (60.6%)                |         |
| —Hepatic encephalopathy | 202 (34.6%)          | 29 (69.0%)        | 173 (32.0%)                |         |
| —Varices                 | 291 (49.9%)          | 30 (71.4%)        | 261 (48.2%)                |         |
| —TIPS                    | 61 (10.5%)           | 6 (14.3%)         | 55 (10.2%)                 |         |
| Disease severity scoring |                      |                   |                            |         |
| —Median CCI              | 5 (5)                | 8 (4)             | 5 (5)                      | <0.05   |
| —Median ASA classification| 3 (1)                | 4 (1)             | 3 (1)                      | <0.05   |
| —Median mayo surgical risk score, 30-day | 7% (10%) | 12% (22%) | 6% (9%) | <0.05 |
| Decompensated cirrhosis | 381 (65.4%)          | 34 (81.0%)        | 347 (64.1%)                |         |
| Home medications         |                      |                   |                            |         |
| Lactulose                | 122 (20.9%)          | 22 (52.4%)        | 100 (18.5%)                |         |
| Rifaximin                | 57 (9.8%)            | 16 (38.1%)        | 41 (7.6%)                  |         |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CCI, Charlson Comorbidity Index; CTP, Child-Turcotte-Pugh; HE, hepatic encephalopathy; INR, international normalized ratio; IQR, interquartile range; MELD-Na, model for end-stage liver disease; Na, sodium; TIPS, transjugular intrahepatic portosystemic shunt.

**Postoperative hepatic encephalopathy and in-hospital mortality**

In-hospital mortality occurred in 34 (5.8%) individuals. On multivariable cox regression with postoperative HE as a time-dependent covariate, there was a trend towards an increased risk of in-
hospital mortality after the development of postoperative HE (adjusted HR 1.71, 95%CI 0.73–3.98). Higher ASA class significantly increased risk of in-hospital mortality (adjusted HR 2.46, 95%CI 1.21–5.02) (Table 5).

**DISCUSSION**

The postoperative period is a uniquely vulnerable time for patients with cirrhosis. HE is a morbid complication that interferes with the patient’s capacity to follow postoperative instructions, meet nutritional goals, and increases the risk of nosocomial complications. Identifying risk factors for postoperative HE is important to improving care for patients with cirrhosis through risk stratification, developing informed postoperative expectations, and, speculatively, strategizing prophylactic approaches. To date, however, it is neither clear how many or which patients develop postoperative HE nor what the impact of HE on outcomes could be. Our study extends on the literature on postoperative risk assessment in multiple ways.

**Postoperative HE is uncommon**

The incidence of postoperative HE is approximately 7.2% in patients with cirrhosis. Postoperative HE has received little attention. A study of the association between MELD-Na and postoperative outcomes in the National Surgical Quality Improvement Program through 2014 did not assess the incidence or impact of HE but concluded that MELD-Na alone underestimated risk. A recent national sample of 8,193 veterans with cirrhosis undergoing surgery did not evaluate HE...

**TABLE 2** Perioperative data

|                         | All Patients N = 583 | Develop HE N = 42 | Did not Develop HE N = 541 |
|-------------------------|----------------------|-------------------|--------------------------|
| **Preoperative medications, 48 h preoperatively** |                       |                   |                          |
| Lactulose               | 34 (5.8%)            | 10 (23.8%)        | 24 (4.4%)                |
| Median total dose       | 46 (80)              | 70 (74)           | 40 (65)                  |
| Rifaximin               | 20 (3.4%)            | 6 (14.3%)         | 14 (2.6%)                |
| Diuretics               | 24 (4.1%)            | 2 (4.8%)          | 22 (4.1%)                |
| Nonselective beta blockers | 6 (1.0%)           | 1 (2.4%)          | 5 (0.9%)                 |
| **Intraoperative anesthesia** | 531 (91.1%)       | 38 (90.5%)        | 493 (91.1%)              |
| **Postoperative medications, 48 h postoperatively** |                       |                   |                          |
| Lactulose               | 59 (10.1%)           | 14 (33.3%)        | 45 (8.3%)                |
| Median total dose, 24 h postoperatively | 20 (40)            | 5 (40)            | 20 (40)                  |
| Median total dose, 48 h postoperatively | 40 (65)            | 50 (115)          | 40 (60)                  |
| Rifaximin               | 38 (6.5%)            | 11 (26.2%)        | 27 (5.0%)                |
| Opioids                 | 379 (65.0%)          | 26 (61.9%)        | 353 (65.2%)              |
| Acetaminophen           | 250 (42.9%)          | 9 (21.4%)         | 241 (44.5%)              |
| NSAIDs                  | 59 (10.1%)           | 3 (7.1%)          | 56 (10.4%)               |
| Anti-psychotics         | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)                 |
| Benzodiazepines         | 68 (11.7%)           | 7 (16.7%)         | 61 (11.3%)               |
| Diuretics               | 78 (13.4%)           | 7 (16.7%)         | 71 (13.1%)               |
| Nonselective beta blockers | 17 (2.9%)          | 2 (4.8%)          | 15 (2.8%)                |
| **Postoperative complications** |                       |                   |                          |
| Development of AKI<sup>b</sup> | 71 (12.2%)       | 10 (23.8%)        | 61 (11.3%)               |
| Development of hypoglycemia<sup>b</sup> | 21 (3.6%)         | 1 (2.4%)          | 20 (3.7%)                |
| Development of postoperative infection<sup>a</sup> | 121 (20.8%)       | 19 (45.2%)        | 102 (18.9%)              |

Abbreviations: AKI, acute kidney injury; HE, hepatic encephalopathy; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs.

<sup>a</sup>Refers to development of infection during the postoperative course, prior to the development of hepatic encephalopathy.

<sup>b</sup>Within five days postoperatively, or prior to the development of postoperative HE, whichever occurred first.
Postoperative HE may be predictable

We used multistate modeling to determine risk factors for postoperative HE that account for the competing risk of in-hospital mortality and AKI. Our model suggests that patients with a history of HE are at increased risk of postoperative HE, and that this risk is highest in the first five postoperative days, while those without prior HE experience more linear risk of postoperative HE, likely with a risk that parallels the complexity of their postoperative course (Figure 1).

Understanding the patient’s risk of HE informs clinical management.

Patients with advanced disease, a history of cirrhosis complications, or high scores on existing models, may benefit from (1) increased vigilance for HE symptoms postoperatively; (2) appropriate HE prophylaxis prior to and after surgery (lactulose, rifaximin); and (3) close follow-up to minimize the risk of HE.

TABLE 3 Overall outcomes and by procedure type

| Procedure Type                      | N (%) | Develop HE (7.2%) | Did Not Develop HE (92.8%) | Median LOS, days (IQR) | In-hospital mortality |
|-------------------------------------|-------|------------------|---------------------------|------------------------|-----------------------|
| Overall                             | 583   | 42 (7.2%)        | 541 (92.8%)               | 7.0 (12.0) / 26.5 (25.7) | 5.8%                  |
| Abdominal                           | 71    | 12 (12.2%)       | 59 (33.3%)                | 7.0 (12.0)             | 7.0%                  |
| Abdominal Non-bowel                 | 194   | (33.3%)          | 171 (69.0%)               | 6.0 (9.0)              | 7.2%                  |
| Cardiac                             | 99    | (17.0%)          | 80 (80%)                  | 12.0 (14.0)            | 8.1%                  |
| Head & Neck I&D                     | 35    | (6.0%)           | 31 (88.6%)                | 8.0 (8.0)              | 0.0%                  |
| I&D                                 | 105   | (18.0%)          | 95 (89.6%)                | 14.0 (19.0)            | 3.8%                  |
| Orthopedic                          | 26    | (4.5%)           | 20 (76.9%)                | 5.0 (5.0)              | 0.0%                  |
| Spine                               | 14    | (2.4%)           | 12 (85.7%)                | 8.0 (11.7)             | 0.0%                  |
| Thoracic                            | 34    | (5.8%)           | 31 (91.2%)                | 5.0 (8.5)              | 8.8%                  |
| Vascular                            | 5     | (6.0%)           | 4 (80%)                   | 10.0 (10.2)            | 0.0%                  |

Abbreviations: HE, hepatic encephalopathy; I&D, incision and drainage; IQR, interquartile range; LOS = length of stay.

aP < 0.05.

bIncludes patients discharged without developing HE (517%, 88.7%) and patients who died without developing HE (24%, 4.1%).

FIGURE 1 History of hepatic encephalopathy and risk of postoperative hepatic encephalopathy. Abbreviations: HE, hepatic encephalopathy.
consideration of optimization with subspecialty consultation prior to elective procedures. Consultation with gastroenterologists/hepatologists prior to planned operations for persons with cirrhosis is associated with improved postoperative outcomes. The role of inpatient consultation in the perioperative period would benefit from multicenter/national database studies.

Contextual factors

Our data was derived over a 10-year period at a single-center academic health system and may not reflect the characteristics and risk factors of the broader population. Additionally, some of the risk factors have inherent limitations, such as the subjective nature of ASA physical classification grading and inability to input values of II or V into the Mayo risk score. Patients who developed HE prior to surgery were not included as they did not develop HE postoperatively, which limits the ability of this study to assess for worsening of HE postoperatively. The retrospective nature of the data and assessing a diagnosis of HE as documented in the electronic medical record by different physicians is another limitation. Additionally, it is difficult to draw conclusions based on preoperative lactulose or rifaximin usage, given that only medications given during the admission would be recorded in the electronic health record. Another limitation is the nature of surgery, many procedures were done non-electively, which limits pre-procedural interventions that can be

### Table 4: Unadjusted and adjusted hazard ratios for postoperative HE

| Postoperative HE                        | Unadjusted Subdistribution Hazard Ratio (95%CI) | Adjusted Subdistribution Hazard Ratio (95%CI) |
|-----------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Age (per 10 years)                      | 0.96 (0.78–1.18), p = 0.69                    | 1.04 (0.82–1.33), p = 0.78                    |
| MELD-Na                                 | 1.07 (1.04–1.11), p = <0.001                   | 1.03 (0.99–1.07), p = 0.058                    |
| ASA class                               | 2.7 (1.7–4.3), p = <0.001                      | 2.12 (1.25–3.60), p = 0.0065                   |
| History of HE                           | 4.49 (2.35–8.59), p = <0.001                   | 4.12 (2.07–8.21), p = <0.001                   |
| History of ascites                      | 2.03 (1.0–4.12), p = 0.048                     | 0.79 (0.37–1.70), p = 0.59                     |
| TIPS                                    | 1.48 (0.62–3.53), p = 0.38                     |                                              |
| Intraoperative general anesthesia       | 0.91 (0.32–2.58), p = 0.86                     |                                              |
| Postoperative benzodiazepine            | 1.55 (0.69–3.46), p = 0.29                     |                                              |
| Postoperative opioid                    | 0.88 (0.47–1.63), p = 0.68                     |                                              |
| Postoperative diuretics                 | 1.32 (0.59–2.99), p = 0.50                     |                                              |
| Postoperative beta blocker              | 1.75 (0.41–7.43), p = 0.45                     |                                              |
| Postoperative AKI                       | 2.27 (1.12–4.57), p = 0.022                    |                                              |
| Postoperative hypoglycemia              | 1.28 (0.31–5.22), p = 0.73                     |                                              |
| Postoperative infection                  | 3.25 (1.78–5.94), p = <0.001                   |                                              |
| Nonelective procedure                   | 2.51 (1.31–4.81), p = 0.0056                   |                                              |
| 30-Day Mayo risk score (unit 1%)        | 1.03 (1.01–1.04), p = <0.001                   |                                              |

Abbreviations: AKI, acute kidney injury; ASA, American Society of Anesthesiologists; CI, confidence interval; HE, hepatic encephalopathy; MELD-Na, Model for End-Stage Liver Disease Sodium; TIPS, transjugular intrahepatic portosystemic shunt.

### Table 5: Unadjusted and adjusted hazard ratios for postoperative in-hospital mortality

| Postoperative Death                     | Unadjusted Hazard Ratio (95%CI) | Adjusted Hazard Ratio (95%CI) |
|-----------------------------------------|---------------------------------|------------------------------|
| Age (per 10 years)                      | 1.08 (0.82–1.42), p = 0.58      | 1.09 (0.80–1.49), p = 0.58   |
| MELD-Na                                 | 1.04 (1.01–1.08), p = 0.022      | 1.0 (0.95–1.04), p = 0.84    |
| ASA class                               | 2.59 (1.44–4.65), p = 0.0014     | 2.46 (1.21–5.02), p = 0.013  |
| Postop HE                               | 2.12 (0.94–4.76), p = 0.070      | 1.71 (0.73–3.98), p = 0.22   |
| History of ascites                      | 1.37 (0.58–3.21), p = 0.47       | 1.30 (0.50–3.38), p = 0.59   |

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; HE, hepatic encephalopathy; MELD-Na, Model for End-Stage Liver Disease Sodium.
taken to minimize the risk of developing postoperative HE. Finally, we had hypothesized that exposure to opioids or benzodiazepines would increase risk. No association was detected in this study. However, we cannot exclude the possibility that sample exposed was too small or confounded by indication to observe an effect. This is especially true in the case of benzodiazepines, where the point estimate hazard ratio is 1.55 and prior research would suggest they do confer an increased risk for HE.  

CONCLUSIONS

Postoperative HE is neither common nor rare but it substantially increases the risk of patient harm. The prevalence identified in this study is largely reflective of CTP Class A and B patients who were not having ongoing encephalopathy prior to their procedure. The prevalence of postoperative HE in CTP Class C patients may be increased, as seen within the small subset of Class C patients in this study. Multicenter data are needed to confirm these findings. However, interventions including monitoring protocols and prophylactic therapies merit further study.

ACKNOWLEDGEMENTS

Elliot Tapper receives funding from the National Institutes of Health through the NIDDK (1K23DK117055-01A1). Jeremy Louissaint received support through the T32DK062708. Zachary Saleh is the guarantor of this article.

AUTHORS CONTRIBUTIONS

Zachary M Saleh: Conceptualization, Data Acquisition, Analysis, Writing Quintin P Solano: Data Acquisition, Writing Jeremy Louissaint: Data Acquisition, Analysis, Writing PeterJepsen: Writing Elliot B. Tapper: Conceptualization, Analysis, Writing

CONFLICTS OF INTEREST

Elliot Tapper has served as a consultant to Norvartis, Kaleido, and Allergan, has served on advisory boards for Mallinckrodt, Rebiotix, and Bausch Health, and has received unrestricted research grants from Gilead.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Zachary M. Saleh https://orcid.org/0000-0001-9273-2417

REFERENCES

1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60 (8):646–9. https://doi.org/10.1002/bjs.1800600817
2. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31 (4):864–71. https://doi.org/10.1053/he.2000.5852
3. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132 (4):1261–69. https://doi.org/10.1053/j.gastro.2007.01.040
4. Friedman LS. Surgery in the patient with liver disease. 14.
5. Nguyen GC, Correia AJ, Thuluvath PJ. The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide. Population-Based Study: Dis Colon Rectum. 2009;52 (8):1367–74. https://doi.org/10.1007/DCR.0b013e3181a80dca
6. Nakeeb AE. Impact of cirrhosis on surgical outcome after pancreatoduodenectomy. World J Gastroenterol. 2013;19 (41):7129. https://doi.org/10.3748/wjg.v19.i41.7129
7. Odom SR, Gupta A, Talmor D, Novack V, Sagy I, Evenson AR. Emergency hernia repair in cirrhotic patients with ascites. J Trauma Acute Care Surg. 2013;75 (3):404–9. https://doi.org/10.1097/TA.0b013e31829e2313
8. Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery. 1997;122 (4):730–6. https://doi.org/10.1016/S0039-6060(97)90080-5
9. Leeds IL, Canner JK, Gani F, Meyers PM, Haut ER, Efron JE, et al. Increased healthcare utilization for medical comorbidities prior to surgery improves postoperative outcomes. Ann Surg. 2019;271 (1):8.
10. Millwala F. Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management. World J Gastroenterol. 2007;13 (30):4056. https://doi.org/10.3748/wjg.v13.i30.4056
11. Robinson TN, Raeburn CD, Tran ZV, Angles EM, Brenner LA. Post-operative delirium in the elderly. Ann Surg. 2009;249 (1):4056. https://doi.org/10.3748/wjg.v13.i30.4056
12. Tapper EB, Ricev-Neyman Y, Sengupta N. Psychoactive medications increase the risk of falls and fall-related injuries in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13 (9):6.
13. Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic encephalopathy impacts the predictive value of the fried frailty index. Published online 2019:10.
14. Gustamante J, Rimola A, Ventura P, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30 (5):890–5. https://doi.org/10.1016/S0168-8278(99)80144-5
15. Fichet J, Mercier E, Genée O, Garot D, Legras A, Dequin P-F, et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care. 2009;24 (3):364–70. https://doi.org/10.1016/j.jcrc.2009.01.008
16. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130 (6):1652–60. https://doi.org/10.1053/j.gastro.2006.02.010
17. Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inf. 2015;55:290–300. https://doi.org/10.1016/j.jbi.2015.05.003
18. Meira-Machado L, de Uña-Alvarez L, Cadarso-Suárez C, Andersen PK. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18 (2):195–222. https://doi.org/10.1177/0962280208092301
19. RStudio Team. RStudio: Integrated Development for R. RStudio, Inc.; 2018
20. Maassel NL, Fleming MM, Luo J, Zhang Y, Pei KY. Model for end-stage liver disease sodium as a predictor of surgical risk in cirrhotic patients with ascites. J Surg Res. 2020;250:45–52. https://doi.org/10.1016/j.jss.2019.12.037

21. Johnson KM, Newman KL, Green PK, Berry K, Cornia PB, Wu P, et al. Incidence and risk factors of postoperative mortality and morbidity after elective versus emergent abdominal surgery in a national sample of 8193 patients with cirrhosis. Ann Surg. Published online October 2019:1. https://doi.org/10.1097/SLA.0000000000003674

22. Grønbæk L, Watson H, Vilstrup H, Jepsen P. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites. United European Gastroenterol J. 2018;6(3):407–12. https://doi.org/10.1177/2050640617727179

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Saleh ZM, Solano QP, Louissaint J, Jepsen P, Tapper EB. The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. United European Gastroenterol J. 2021;9(6):672–80. https://doi.org/10.1002/ueg2.12104